(Q40468582)

20 September 2017

title

Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers. (English)

1 reference

20 September 2017

4

Joseph Sodroski

1 reference

20 September 2017

Wen Yuan

1

1 reference

20 September 2017

Stewart Craig

series ordinal

2

1 reference

20 September 2017

Xinzhen Yang

series ordinal

3

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

332

1 reference

20 September 2017

issue

1

1 reference

20 September 2017

page(s)

369-383

1 reference

Evaluation of on-line high-performance size-exclusion chromatography, differential refractometry, and multi-angle laser light scattering analysis for the monitoring of the oligomeric state of human immunodeficiency virus vaccine protein antigen

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Why do we not have an HIV vaccine and how can we make one? .

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Designing CD4 immunoadhesins for AIDS therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

HIV entry and its inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Expression, purification, and characterization of gp160e, the soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Mechanisms of viral membrane fusion and its inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

The human immunodeficiency virus type 1 envelope glycoprotein precursor acquires aberrant intermolecular disulfide bonds that may prevent normal proteolytic processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

HIV-1 entry inhibitors in the side pocket

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

7 January 2021

Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

7 January 2021

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

7 January 2021

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.11.013

7 January 2021

10.1016/J.VIROL.2004.11.013

Identifiers

DOI

1 reference

20 September 2017

1 reference